Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: Results of a systematic overview

HIV Clinical Trials

Volumn 8, Issue 4, 2007, Pages 221-226

  Bartlett, John A ^a,d   Chen, Shan Shan ^b   Quinn, Joseph B ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GILEAD SCIENCES   (United States)

^c GILEAD SCIENCES INC   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Efavirenz; NRTI combinations; Treatment na ve

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEMOGRAPHY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 34548220391     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0804-221     Document Type: Article

References (19)

1. DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; October 10, 2006. Available at: http://www.aidsinfo.nih. gov/ContentFiles/ AdultandAdolescentGL.pdf
2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA. 2006;296:827-843
3. Gulick RM, Ribaudo HJ, Shikuma CM, et al Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.
4. Gallant JE, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3 year randomized trial. JAMA. 2004;292:191-201.
5. Gallant J, DeJesus E, Arribas J, et al. The combination of tenofovir disoproxyl fumarate, emtricitabine and efavirenz produces superior outcomes compared to fixed dose zidovudine-lamivudine and efavirenz in antiretroviral-naïve patients (Study GS-934). N Engl J Med. 2006;354:251-260.
6. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
7. Sustiva Package Insert. Bristol Myers Squibb.
8. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-2315.
9. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
10. Bartlett JA, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir or stavudine. J Acquir Immune Defic Syndr. 2006;43:284-292.
11. US Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA levels - clinical considerations for accelerated and traditional approval. October 2002. Available at: http://www.fda.gov/Cder/ guidance/3647fnl.htm
12. Saag M, Cahn P, Raffi F, et al. Safety and efficacy of emtricitabine vs. stavudine in combination therapy in antiretroviral-naïve patients (Study FTC-301A). JAMA. 2004;292:180-190.
13. Moyle G, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral naïve HIV-infected adults (Study 30021). J Acquir Immune Defic Syndr. 2005;38:417-425.
14. DeJesus E, Herrera G, Tenfilo E, et al. Abacavir versus zidovudine plus lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adults (Study 30024). Clin Infect Dis. 2004;39:1038-1046.
15. DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naïve adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39(3):411-418. Epub 2004 July 15.
16. Squires K, Thiry A, Giordano M. Atazanvir (ATZ) QD and efavirenz (EFV) QD with fixed dose ZDV+3TC: a comparison of antiviral efficacy and safety through week 24 (AI424-034). In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, CA.
17. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes- a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43(5):535-540.
18. Sanne I, van der Horst C, et al. Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC). In: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Poster 4432.
19. Riddler S, Haubrich R, DiRienzo G, et al. A prospective, randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection- ACTG 5142. In: Program and abstracts of the XVIth International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB 0204.